The present invention provides pharmaceutical compositions comprising a morphogenic
protein stimulatory factor (MPSF) for improving the tissue inductive activity of
morphogenic proteins, particularly those belonging to the BMP protein family. Methods
for improving the tissue inductive activity of a morphogenic protein in a mammal
using those compositions are provided. This invention also provides implantable
morphogenic devices comprising a morphogenic protein and a MPSF disposed within
a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic
implants. Methods for inducing local tissue formation from a progenitor cell in
a mammal using those devices are also provided. A method for accelerating allograft
repair in a mammal using morphogenic devices is provided. This invention also provides
a prosthetic device comprising a prosthesis coated with a morphogenic protein and
a MPSF, and a method for promoting in vivo integration of an implantable prosthetic
device to enhance the bond strength between the prosthesis and the existing target
tissue at the joining site. Methods of treating tissue degenerative conditions
in a mammal using the pharmaceutical compositions are also provided.